Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
14 November 2024 - 11:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Applied Therapeutics, Inc.
(Name of Issuer)
Common Stock $0.0001 par value per share
(Title of Class of
Securities)
03828A101
(CUSIP Number)
September 30, 2024
(Date of Event
Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
¨ |
Rule 13d-1(b) |
x |
Rule 13d-1(c) |
¨ |
Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 03828A101 | Page 2 of 14 |
1. |
Names of Reporting Persons
Venrock Healthcare Capital Partners III, L.P. |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1)
(b) ¨
|
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
11,656,065 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
11,656,065 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
11,656,065 (2) |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
11. |
Percent of Class Represented by Amount in Row (9)
9.99% (3) |
12. |
Type of Reporting Person (See Instructions)
PN |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare
Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the
purposes of this Schedule 13G/A. |
| (2) | Consists of (i) 1,161,543 shares and 502,131 shares issuable upon the exercise of immediately exercisable
warrants (“Warrants”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 116,170 shares and 50,233
shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,547,287 shares and 1,278,701
shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding
sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as
a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not
effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect
to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other
attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. |
| (3) | This percentage is calculated based upon the sum of (i) 114,846,271 shares of the Issuer’s
Common Stock outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 7, 2024; and (ii) 1,831,065 shares issuable upon the exercise of the Warrants described
in Footnote 2 above. |
CUSIP No. 03828A101 | Page 3 of 14 |
1. |
Names of Reporting Persons
VHCP Co-Investment Holdings III, LLC |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1)
(b) ¨
|
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
11,656,065 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
11,656,065 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
11,656,065 (2) |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
11. |
Percent of Class Represented by Amount in Row (9)
9.99% (3) |
12. |
Type of Reporting Person (See Instructions)
OO |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare
Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the
purposes of this Schedule 13G/A. |
| (2) | Consists of (i) 1,161,543 shares and 502,131 shares issuable upon the exercise of immediately exercisable
Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 116,170 shares and 50,233 shares issuable upon the exercise
of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,547,287 shares and 1,278,701 shares issuable upon the exercise
of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number
of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership
provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant,
and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number
of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99%
of the number of shares of common stock outstanding immediately after giving effect to the exercise. |
| (3) | This percentage is calculated based upon the sum of (i) 114,846,271 shares of the Issuer’s
Common Stock outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 7, 2024; and (ii) 1,831,065 shares issuable upon the exercise of the Warrants described
in Footnote 2 above. |
CUSIP No. 03828A101 | Page 4 of 14 |
1. |
Names of Reporting Persons
Venrock Healthcare Capital Partners EG, L.P. |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1)
(b) ¨
|
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
11,656,065 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
11,656,065 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
11,656,065 (2) |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
11. |
Percent of Class Represented by Amount in Row (9)
9.99% (3) |
12. |
Type of Reporting Person (See Instructions)
PN |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare
Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the
purposes of this Schedule 13G/A. |
| (2) | Consists of (i) 1,161,543 shares and 502,131 shares issuable upon the exercise of immediately exercisable
Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 116,170 shares and 50,233 shares issuable upon the exercise
of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,547,287 shares and 1,278,701 shares issuable upon the exercise
of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number
of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership
provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant,
and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number
of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99%
of the number of shares of common stock outstanding immediately after giving effect to the exercise. |
| (3) | This percentage is calculated based upon the sum of (i) 114,846,271 shares of the Issuer’s
Common Stock outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 7, 2024; and (ii) 1,831,065 shares issuable upon the exercise of the Warrants described
in Footnote 2 above. |
CUSIP No. 03828A101 | Page 5 of 14 |
1. |
Names of Reporting Persons
VHCP Management III, LLC |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1)
(b) ¨
|
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
11,656,065 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
11,656,065 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
11,656,065 (2) |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
11. |
Percent of Class Represented by Amount in Row (9)
9.99% (3) |
12. |
Type of Reporting Person (See Instructions)
OO |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare
Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the
purposes of this Schedule 13G/A. |
| (2) | Consists of (i) 1,161,543 shares and 502,131 shares issuable upon the exercise of immediately exercisable
Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 116,170 shares and 50,233 shares issuable upon the exercise
of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,547,287 shares and 1,278,701 shares issuable upon the exercise
of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number
of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership
provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant,
and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number
of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99%
of the number of shares of common stock outstanding immediately after giving effect to the exercise. |
| (3) | This percentage is calculated based upon the sum of (i) 114,846,271 shares of the Issuer’s
Common Stock outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 7, 2024; and (ii) 1,831,065 shares issuable upon the exercise of the Warrants described
in Footnote 2 above. |
CUSIP No. 03828A101 | Page 6 of 14 |
1. |
Names of Reporting Persons
VHCP Management EG, LLC |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1)
(b) ¨
|
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
11,656,065 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
11,656,065 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
11,656,065 (2) |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
11. |
Percent of Class Represented by Amount in Row (9)
9.99% (3) |
12. |
Type of Reporting Person (See Instructions)
OO |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare
Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the
purposes of this Schedule 13G/A. |
| (2) | Consists of (i) 1,161,543 shares and 502,131 shares issuable upon the exercise of immediately exercisable
Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 116,170 shares and 50,233 shares issuable upon the exercise
of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,547,287 shares and 1,278,701 shares issuable upon the exercise
of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number
of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership
provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant,
and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number
of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99%
of the number of shares of common stock outstanding immediately after giving effect to the exercise. |
| (3) | This percentage is calculated based upon the sum of (i) 114,846,271 shares of the Issuer’s
Common Stock outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 7, 2024; and (ii) 1,831,065 shares issuable upon the exercise of the Warrants described
in Footnote 2 above. |
CUSIP No. 03828A101 | Page 7 of 14 |
1. |
Names of Reporting Persons
Shah, Nimish |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1)
(b) ¨
|
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
United States |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
11,656,065 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
11,656,065 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
11,656,065 (2) |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
|
11. |
Percent of Class Represented by Amount in Row (9)
9.99% (3) |
12. |
Type of Reporting Person (See Instructions)
IN |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare
Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the
purposes of this Schedule 13G/A. |
| (2) | Consists of (i) 1,161,543 shares and 502,131 shares issuable upon the exercise of immediately exercisable
Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 116,170 shares and 50,233 shares issuable upon the exercise
of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,547,287 shares and 1,278,701 shares issuable upon the exercise
of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number
of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership
provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant,
and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number
of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99%
of the number of shares of common stock outstanding immediately after giving effect to the exercise. |
| (3) | This percentage is calculated based upon the sum of (i) 114,846,271 shares of the Issuer’s
Common Stock outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 7, 2024; and (ii) 1,831,065 shares issuable upon the exercise of the Warrants described
in Footnote 2 above. |
CUSIP No. 03828A101 | Page 8 of 14 |
1. |
Names of Reporting Persons
Koh, Bong |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) x (1)
(b) ¨
|
3. |
SEC Use Only
|
4. |
Citizenship or Place of Organization
United States |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
11,656,065 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
11,656,065 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
11,656,065 (2) |
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
9.99% (3) |
12. |
Type of Reporting Person (See Instructions)
IN |
| (1) | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare
Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the
purposes of this Schedule 13G/A. |
| (2) | Consists of (i) 1,161,543 shares and 502,131 shares issuable upon the exercise of immediately exercisable
Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 116,170 shares and 50,233 shares issuable upon the exercise
of Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 8,547,287 shares and 1,278,701 shares issuable upon the exercise
of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number
of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership
provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant,
and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number
of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99%
of the number of shares of common stock outstanding immediately after giving effect to the exercise. |
| (3) | This percentage is calculated based upon the sum of (i) 114,846,271 shares of the Issuer’s
Common Stock outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 7, 2024; and (ii) 1,831,065 shares issuable upon the exercise of the Warrants described
in Footnote 2 above. |
CUSIP No. 03828A101 | Page 9 of 14 |
Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Applied Therapeutics, Inc.
Item 1. |
|
(a) |
Name of Issuer
Applied Therapeutics, Inc. |
|
|
(b) |
Address of Issuer’s Principal Executive Offices
545 Fifth Avenue, Suite 1400
New York, NY 10017 |
|
Item 2. |
|
(a) |
Name of Person Filing
Venrock Healthcare Capital Partners III, L.P.
VHCP Co-Investment Holdings III, LLC
Venrock Healthcare Capital Partners EG, L.P.
VHCP Management III, LLC
VHCP Management EG, LLC
Nimish Shah
Bong Koh |
|
(b) |
Address of Principal Business Office or, if none, Residence |
|
|
|
|
|
New York Office: |
Palo Alto Office: |
|
|
|
|
|
7 Bryant Park |
3340 Hillview Avenue |
|
|
23rd Floor |
Palo Alto, CA 94304 |
|
|
New York, NY 10018 |
|
(c) |
Citizenship
All of the Venrock Entities were organized in
Delaware. The individuals are both United States citizens. |
|
|
(d) |
Title of Class of Securities
Common Stock $0.0001 par value |
|
|
|
|
(e) |
CUSIP Number
03828A101 |
CUSIP No. 03828A101 | Page 10 of 14 |
Item 3. |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
|
Not applicable |
|
Item 4. |
Ownership |
|
(a) |
Amount beneficially owned as of September 30, 2024: |
|
Venrock Healthcare Capital Partners III, L.P. | |
| 11,656,065 | (1) |
|
VHCP Co-Investment Holdings III, LLC | |
| 11,656,065 | (1) |
|
Venrock Healthcare Capital Partners EG, L.P. | |
| 11,656,065 | (1) |
|
VHCP Management III, LLC | |
| 11,656,065 | (1) |
|
VHCP Management EG, LLC | |
| 11,656,065 | (1) |
|
Nimish Shah | |
| 11,656,065 | (1) |
|
Bong Koh | |
| 11,656,065 | (1) |
|
(b) |
Percent of class as of September 30, 2024: |
|
Venrock Healthcare Capital Partners III, L.P. | |
| 9.99 | %(2) |
|
VHCP Co-Investment Holdings III, LLC | |
| 9.99 | %(2) |
|
Venrock Healthcare Capital Partners EG, L.P. | |
| 9.99 | %(2) |
|
VHCP Management III, LLC | |
| 9.99 | %(2) |
|
VHCP Management EG, LLC | |
| 9.99 | %(2) |
|
Nimish Shah | |
| 9.99 | %(2) |
|
Bong Koh | |
| 9.99 | %(2) |
|
|
(c) |
Number of shares as to which the person has, as of September 30, 2024: |
|
(i) |
Sole power to vote or to direct the vote: |
|
Venrock Healthcare Capital Partners III, L.P. | |
|
0 |
|
VHCP Co-Investment Holdings III, LLC | |
|
0 |
|
Venrock Healthcare Capital Partners EG, L.P. | |
|
0 |
|
VHCP Management III, LLC | |
|
0 |
|
VHCP Management EG, LLC | |
|
0 |
|
Nimish Shah | |
|
0 |
|
Bong Koh | |
|
0 |
|
|
(ii) |
Shared power to vote or to direct the vote: |
|
Venrock Healthcare Capital Partners III, L.P. | |
| |
11,656,065(1) |
|
VHCP Co-Investment Holdings III, LLC | |
| |
11,656,065(1) |
|
Venrock Healthcare Capital Partners EG, L.P. | |
| |
11,656,065(1) |
|
VHCP Management III, LLC | |
| |
11,656,065(1) |
|
VHCP Management EG, LLC | |
| |
11,656,065(1) |
|
Nimish Shah | |
| |
11,656,065(1) |
|
Bong Koh | |
| |
11,656,065(1) |
CUSIP No. 03828A101 | Page 11 of 14 |
|
(iii) |
Sole power to dispose or to direct the disposition of: |
|
Venrock Healthcare Capital Partners III, L.P. | |
| |
0 |
|
VHCP Co-Investment Holdings III, LLC | |
| |
0 |
|
Venrock Healthcare Capital Partners EG, L.P. | |
| |
0 |
|
VHCP Management III, LLC | |
| |
0 |
|
VHCP Management EG, LLC | |
| |
0 |
|
Nimish Shah | |
| |
0 |
|
Bong Koh | |
| |
0 |
|
(iv) |
Shared power to dispose or to direct the disposition of: |
|
Venrock Healthcare Capital Partners III, L.P. | |
| |
11,656,065(1) |
|
VHCP Co-Investment Holdings III, LLC | |
| |
11,656,065(1) |
|
Venrock Healthcare Capital Partners EG, L.P. | |
| |
11,656,065(1) |
|
VHCP Management III, LLC | |
| |
11,656,065(1) |
|
VHCP Management EG, LLC | |
| |
11,656,065(1) |
|
Nimish Shah | |
| |
11,656,065(1) |
|
Bong Koh | |
| |
11,656,065(1) |
(1) Consists
of (i) 1,161,543 shares and 502,131 shares issuable upon the exercise of immediately exercisable Warrants held by Venrock Healthcare
Capital Partners III, L.P.; (ii) 116,170 shares and 50,233 shares issuable upon the exercise of Warrants held by VHCP Co-Investment
Holdings III, LLC; and (iii) 8,547,287 shares and 1,278,701 shares issuable upon the exercise of Warrants held by Venrock Healthcare
Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable
upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following
sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled
to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially
owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common
stock outstanding immediately after giving effect to the exercise.
VHCP Management
III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC.
VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting
members of VHCP Management III, LLC and VHCP Management EG, LLC.
(2) This
percentage is calculated based upon the sum of (i) 114,846,271 shares of the Issuer’s Common Stock outstanding as of August 6,
2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7,
2024; and (ii) 1,831,065 shares issuable upon the exercise of the Warrants described in Footnote 1 above. |
CUSIP No. 03828A101 | Page 12 of 14 |
Item 5. |
Ownership
of Five Percent or Less of a Class |
|
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following ¨ |
|
Item 6. |
Ownership
of More than Five Percent on Behalf of Another Person |
|
Not applicable |
|
Item 7. |
Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
|
Not applicable |
|
Item 8. |
Identification and Classification of Members of the Group |
|
Not applicable |
|
Item 9. |
Notice of Dissolution of Group |
|
Not applicable |
|
Item 10. |
Certification |
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. |
CUSIP No. 03828A101 | Page 13 of 14 |
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: November 14, 2024
Venrock Healthcare Capital Partners III, L.P. |
|
Venrock Healthcare Capital Partners EG, L.P. |
|
|
|
By: |
VHCP Management III, LLC |
|
By: |
VHCP Management EG, LLC |
Its: |
General Partner |
|
Its: |
General Partner |
|
|
|
By: |
/s/ Sherman G. Souther |
|
By: |
/s/ Sherman G. Souther |
|
Name: Sherman G. Souther |
|
|
Name: Sherman G. Souther |
|
Its: Authorized Signatory |
|
|
Its: Authorized Signatory |
|
|
|
VHCP Co-Investment Holdings III, LLC |
|
|
|
|
|
By: |
VHCP Management III, LLC |
|
|
Its: |
Manager |
|
|
|
|
|
By: |
/s/ Sherman G. Souther |
|
|
|
Name: Sherman G. Souther |
|
|
|
Its: Authorized Signatory |
|
|
|
|
|
VHCP Management III, LLC |
|
VHCP Management EG, LLC |
|
|
|
By: |
/s/ Sherman G. Souther |
|
By: |
/s/ Sherman G. Souther |
|
Name: Sherman G. Souther |
|
|
Name: Sherman G. Souther |
|
Its: Authorized Signatory |
|
|
Its: Authorized Signatory |
|
|
|
Nimish Shah |
|
|
|
|
|
/s/ Sherman G.
Souther |
|
|
Sherman G. Souther, Attorney-in-fact |
|
|
|
|
|
Bong Koh |
|
|
|
|
|
/s/ Sherman G.
Souther |
|
|
Sherman G. Souther, Attorney-in-fact |
|
|
CUSIP No. 03828A101 | Page 14 of 14 |
EXHIBITS
Applied Therapeutics (NASDAQ:APLT)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Applied Therapeutics (NASDAQ:APLT)
Historical Stock Chart
Von Nov 2023 bis Nov 2024